The eMAG builds on the NucliSENS easyMAG platform. The firm said it features automation from the primary sample tube, greater traceability and higher throughput than the previous system.
Extraction is the first step of molecular biology testing, making it possible to get purified nucleic acids to be amplified and detected.
Efficiency of nucleic acid extraction from a sample impacts the quality of a diagnostic test’s final result and because there may be various sample types, it is complex, said bioMérieux.
The eMAG system can be used with biological samples such as whole blood, plasma, serum, stool, respiratory samples and cerebrospinal fluid.
It uses BOOM technology for extraction of DNA and RNA and can extract 48 samples in 90 minutes from a primary sample, and handles all sample types in one series.
“As pioneers of diagnostics for over 50 years, we are proud to provide our customers with high medical value automated solutions that meet their needs for improved laboratory workflow, optimization, traceability and efficiency,” said Randy Rasmussen, CEO of BioFire Diagnostics and VP Molecular Biology at bioMérieux.
The system is CE-marked and available in Europe and the US and will be rolled out in other countries in early 2017.